VALN Stock Nosedives on Mixed Results From Lyme Disease Vaccine Study

Shares fell 37% after Valneva reported its Lyme vaccine demonstrated >70% efficacy but failed to meet a prespecified key statistical target. The result raises approval and commercialization concerns despite the company’s plans to proceed with regulatory filings, prompting significant investor sell‑off and reduced confidence in the program.

Analysis

Shares fell 37% after Valneva reported its Lyme vaccine demonstrated >70% efficacy but failed to meet a prespecified key statistical target. The result raises approval and commercialization concerns despite the company’s plans to proceed with regulatory filings, prompting significant investor sell‑off and reduced confidence in the program.